monomethylauristatin f

MMAF (MonoMethyl auristatin F), an antimitotic agent, inhibits cell division by blocking the polymerization of tubulin.

D8-MMAF is a microtubule destroyer, deuterated form of MMAF (T3256-GMP).

McMMAF is a protective group-conjugated MMAF. MMAF is a potent tubulin polymerization inhibitor.It is a MMAF derivative having a Maleimidocaproyl linker (MC linker), which is ready to conjugate to antibody or other proteins or biopolymers. Mafodotin is a useful agent for make antibody drug conjugate (ADC) for targeted drug delivery.

MMAF Hydrochloride is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A. MMAF Hydrochloride is an effective tubulin polymerization inhibitor and is used as an antitumor compound.

MMAF sodium is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A. MMAF sodium is an effective tubulin polymerization inhibitor and is used as an antitumor agent.

MMAF-OMe (Monomethyl auristatin F methyl ester) is an antitubulin agent which inhibits several tumor cell lines with IC50s of 0.056 nM, 0.166 nM, 0.183 nM, and 0.449 nM for MDAMB435/5T4, MDAMB361DYT2, MDAMB468, and Raji (5T4-) cell lines, respectively. MMAF-Ome is also an ADC cytotoxin.

OncoFAP-GlyPro-MMAF is a Drug-Linker Conjugate for ADC (antibody-drug conjugate) that exhibits potent antitumor activity. It is composed of Monomethylauristatin F and a linker, and is utilized in the synthesis of ADCs.

MMAFintermediate 1 serves as a precursor in the synthesis of MMAF (Monomethylauristatin F), an effective inhibitor of tubulin polymerization. MMAF is a cytotoxic component commonly used in antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A. This compound plays a crucial role in the production of classic ADC cytotoxins.

MMAF intermediate 2 is a key synthetic intermediate used in the preparation of MMAF, a potent tubulin polymerization inhibitor that serves as the cytotoxic payload in clinically validated antibody-drug conjugates, MMAF intermediate 2 support the scalable synthesis and development of next-generation ADC cytotoxins.